Metagenomi, Inc. - Rasio cepet MGX

This chart of Metagenomi, Inc. (MGX) quotes on the GURU.Markets platform shows a level of 4.47, supported by payments from major gene modification licensing partners. The business relies on authoritative developments in high-precision CRISPR editing and minimizes technological threats by creating cutting-edge tools for correcting hereditary pathologies in collaboration with industry leaders.

The quick ratio measures a company's ability to instantaneously settle short-term obligations using cash and accounts receivable, completely excluding illiquid inventories. This chart's quick liquidity analysis allows for an assessment of the financial stability of Metagenomi, Inc. (MGX), whose strategy for scaling a universal genome editing platform requires a significant reserve of liquid cash to ensure global drug production.